Panitumumab IRDye800 Optical Imaging Study

Trial ID or NCT#

NCT02415881

Status

not recruiting iconNOT RECRUITING

Purpose

Phase I trial to evaluate the safety of escalating dose levels of conjugated panitumumab-IRDye800 in subjects with head and neck squamous cell carcinoma (HNSCC) that undergo surgery with curative intent.

Official Title

Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer During Surgical Procedures

Eligibility Criteria

Ages Eligible for Study: Older than 19 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Vasu Divi, MD
Vasu Divi, MD
Head and neck surgeon
Associate Professor of Otolaryngology - Head & Neck Surgery (OHNS)
Davud Sirjani, MD
Davud Sirjani, MD
Head and neck surgeon
Clinical Professor, Otolaryngology (Head and Neck Surgery)
John B. Sunwoo, MD
John B. Sunwoo, MD
Head and neck surgeon
Edward C. and Amy H. Sewall Professor in the School of Medicine and Professor, by courtesy, of Dermatology
Michael J. Kaplan, MD

Contact us to find out if this trial is right for you.

Contact

Grace Yi
650-242-2666

View on ClinicalTrials.gov